Clinical trial · Interventional
Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy
A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety and Ability of Meritup Oral Liquid to Reduce Fatigue in Patients With Metastatic Breast Cancer Receiving Chemotherapy
NCT06151249CI-TRIAL-00071864unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A randomized, double-blind, placebo-controlled, parallel study to evaluate the safety profile and ability of Meritup oral solution to decrease fatigue in metastatic breast cancer patients receiving chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Meritup oral solution | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Chemotherapy+Meritup
- description
- Chemotherapy+Meritup 20ml TID
- interventionNames
- Combination Product: Meritup oral solution
- type
- PLACEBO_COMPARATOR
- label
- Chemotherapy+Placebo
- description
- Chemotherapy+Placebo 20ml TID
- interventionNames
- Combination Product: Meritup oral solution
Primary outcomes (1)
- measure
- Changes in fatigue scores
- timeFrame
- one months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Female patients over 20years old and under 80 years old. 2. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2), These 3 indicators are all negative. 3. After at least 3 cycles of chemotherapy. 4. Sign the subject Informed Consent Form (ICF). Exclusion Criteria: 1. Have received other clinical studies within 3 weeks 2. Any uncontrollable infection 3. History of lupus erythematosus, rheumatoid arthritis, ankylosing spondylosis, scleroderma or multiple sclerosis 4. History of cancer cells that have metastasized to the brain 5. Currently receiving a mixture of three or more types of cytotoxic chemotherapy drugs 6. Currently using anti-fatigue treatments, including psychostimulants, acupuncture, etc. Note: Antidepressants are used for treatment to relieve fatigue (such as depression or hot flashes) is allowed, 7. Need to use long-acting sustained-release pain narcotic analgesics 8. Uncontrollable nausea, vomiting or other symptoms that will hinder the ability to speak about the test product 9. Any other serious illness/history that would limit the patient's ability to receive study treatment, as determined by the researcher evaluate 10. Lactation, pregnancy or planning pregnancy 11. People with cardiovascular disease or severe liver and kidney dysfunction should not drink it within one week after surgery.
References
Publications (0)
Data not yet available
No reference posted for this study.